AstraZeneca receives EU approval for respiratory syncytial virus drug for infants

AstraZeneca drug producer said its Beyfortus immunization developed with France's Sanofi has received EU approval for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in infants.

As the English ProActiveInvestors website reported, Beyfortus is the first and only single-dose RSV passive immunization for the broad infant population, according to the pharmaceutical company. 

RSV is a common and highly contagious seasonal virus, infecting nearly all children by the age of two.